Company news
Kringle Pharma, Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Kringle Pharma Receives FDA Clearance of IND Application for Oremepermin Alfa in Acute Spinal Cord Injury
October 18, 2026
Kringle Pharma Announces IND Submission to the U.S. FDA for Oremepermin Alfa for the Treatment of Acute Spinal Cord Injury
September 23, 2026
Financial Results for the Nine Months Ended June 30, 2026 [Japanese GAAP] (Non-consolidated)
August 10, 2026
Kringle Pharma Advances the Registrational Program for Oremepermin Alfa in Japan with Initiation of Additional Phase 3 in Acute Spinal Cord Injury
July 23, 2026
Update on the Investigator-initiated Phase 2 Study in Patients with ALS
August 12, 2022
Kringle Pharma Files Patent Application for Treatment of Chronic Spinal Cord Injury
March 11, 2022
Kringle Pharma Appoints Hideyuki Okano, M.D., Ph.D. as Scientific Advisor
February 28, 2022
Financial Results for the Three Months Ended December 31, 2021(Non-consolidated)
February 27, 2022
Kringle Pharma Strengthens IP Portfolio with the Formulation Patent in Europe.
December 29, 2021
［Delayed］Financial Results for the Fiscal Year Ended September 30, 2021 (Non-consolidated)
December 16, 2021
Last Patient Out in Phase 2 Study of KP-100IT for the Treatment of ALS
December 8, 2021
Financial Results for the Nine Months Ended June 30, 2021(Non-consolidated)
August 20, 2021